QA: PUMA Biotechnology INC in us_pharma/2025

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001401667_2026_PUMA_Biotechnology_INC.pdf

Logs

Graph

Absolute values for 0001401667, PUMA Biotechnology INC

  xvar xval
0 AssetsCurrent 162,686,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 187,000
3 remainder_Assets 53,429,000
4 LiabilitiesCurrent 81,253,000
5 LiabilitiesNoncurrent 4,709,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 58,932,239
8 SellingGeneralAndAdministrativeExpense 62,948,550
9 ResearchAndDevelopmentExpense 63,169,026
10 remainder_Expenses 4,834,424
11 remainder_Revenues 227,892,524
12 remainder_NetIncome -1,782,647
13 remainder_ComprehensiveNetIncome 23,911
  yvar yval
0 Assets 216,302,000
1 Liabilities 85,962,000
2 Expenses 189,884,239
3 Revenues 227,892,524
4 StockholdersEquity 130,340,000
5 NetIncome 36,225,638
6 ComprehensiveNetIncome 36,237,594
7 BaseVar 360,923,660
8 EconomicCapitalRatiobeforeLimitedLiability 2.12
9 EconomicCapitalRatio 3.10

Edgar->Model Mapping

Feature Distribution

Change over Time